Congestive heart failure (CHF) describes the condition of fluid build-up in the body as the heart inefficiently fills with or pumps out blood. CHF results from other conditions that weaken the heart muscle including coronary artery disease, myocardial infarction, cardiomyopathy, and hypertension, and is a major public health concern.
At the meeting, the CTAF panel voted nine to one that Entresto provides greater net health benefits to patients than standard care with angiotensin converting enzyme (ACE) inhibitors. A majority of the panel also voted that CardioMEMS improves net health benefits compared to usual care and monitoring, though the votes were closely split, with six of the ten panelists judging the current evidence to be adequate to conclusively state that the device produces improved health outcomes and four judging the evidence to be inadequate. The final report includes a detailed summary of the CTAF’s votes on effectiveness and value, value-based price benchmarks, and key policy recommendations for coverage policy and clinical practice.
For questions, contact email@example.com.
Interventions of interest:
- CardioMEMS™ HF System (St. Jude Medical)
- Sacubitril/valsartan (Entresto™, Novartis)
Below you will find the final documents from the assessment review process: